Here are three quick facts:
1. The InVivo exhibit focuses on raising awareness about the ongoing investigational device exemption pilot trial of its Neuro-Spinal Scaffold in acute spinal cord injury patients.
2. The company’s neurosurgeon collaborators presented preclinical and clinical data at the meeting, including Alexander Ropper, MD, neurosurgeon from the Barrow Neurological Institute in Phoenix, who helped implant the Neuro-Spinal Scaffold into the first subject in the pilot trial.
3. Founded in 2005, InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focusing on the treatment of spinal cord injuries.
More articles on devices:
Chinese 3D-printed artifical bone company looking for investors: 6 key notes
Medtronic gets FDA clearance for ZEVO anterior cervical plate system — 5 things to know
NuVasive Q1 revenue up 8.4% — 10 key notes
